Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study

Background: The incidence of recurrent tinea infections after oral terbinafine therapy is on the rise. Aim: This study aims to identify the appearance of incomplete cure and relapse after 2-week oral terbinafine therapy in tinea corporis and/or tinea cruris. Materials and Methods: A total of 100 consecutive patients clinically and mycologically diagnosed to have tinea corporis and/or tinea cruris were included in the study. The enrolled patients were administered oral terbinafine 250 mg once daily for 2 weeks. All clinically cured patients were then followed up for 12 weeks to look for any relapse/cure. Results: The common dermatophytes grown on culture were Trichophyton rubrum and Trichophyton tonsurans in 55% and 20% patients, respectively. At the end of 2-week oral terbinafine therapy, 30% patients showed a persistent disease on clinical examination while 35% patients showed a persistent positive fungal culture (persisters) at this time. These culture positive patients included all the clinically positive cases. Rest of the patients (65/100) demonstrated both clinical and mycological cure at this time (cured). Over the 12-week follow-up, clinical relapse was seen in 22 more patients (relapse) among those who had shown clinical and mycological cure at the end of terbinafine therapy. Thus, only 43% patients could achieve a long-term clinical and mycological cure after 2 weeks of oral terbinafine treatment. Majority of the relapses (16/22) were seen after 8 weeks of completion of treatment. There was no statistically significant difference in the body surface area involvement or the causative organism involved between the cured, persister, or relapse groups. Conclusions: Incomplete mycological cure as well as relapse is very common after standard (2-week) terbinafine therapy in our patients of tinea cruris/corporis.

[1]  R. Boloor,et al.  A Clinical and Mycological Study of Dermatophytic Infections , 2014, Indian journal of dermatology.

[2]  Amit Kumar,et al.  A comparative study of mycological efficacy of terbinafine and fluconazole in patients of tinea corporis , 2013 .

[3]  S. Hashemi,et al.  In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran , 2013, Iranian journal of pharmaceutical research : IJPR.

[4]  S. Prasad,et al.  INTERMITTENT PULSE-DOSED TERBINAFINE IN THE TREATMENT OF TINEA CORPORIS AND/OR TINEA CRURIS , 2011, Indian Journal of Dermatology.

[5]  S. Abdel‐Rahman,et al.  Update on terbinafine with a focus on dermatophytoses , 2009, Clinical, cosmetic and investigational dermatology.

[6]  M. Friedrich,et al.  Epidemiological trends in skin mycoses worldwide , 2008, Mycoses.

[7]  N. Peres,et al.  Antifungal Resistance Mechanisms in Dermatophytes , 2008, Mycopathologia.

[8]  C. K. Campbell,et al.  Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades. , 2007, Medical mycology.

[9]  C. Fielding,et al.  Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine , 2006, Antimicrobial Agents and Chemotherapy.

[10]  C. Osborne,et al.  Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine , 2005, Antimicrobial Agents and Chemotherapy.

[11]  B. Srikant,et al.  Clinicomycological study of dermatophytosis in Bijapur. , 2004, Indian journal of medical microbiology.

[12]  B. Elewski,et al.  Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. , 2004, Journal of the American Academy of Dermatology.

[13]  C. Janaki,et al.  Scenario of chronic dermatophytosis: An Indian study , 1997, Mycopathologia.

[14]  S. Singh,et al.  Profile of dermatophyte infections in Baroda. , 2003, Indian journal of dermatology, venereology and leprology.

[15]  Aditya K Gupta,et al.  Tinea corporis, tinea cruris, tinea nigra, and piedra. , 2003, Dermatologic clinics.

[16]  P. Roy,et al.  Clinico-mycological Profile of Superficial Mycosis in a Hospital in North-East India. , 2003, Medical journal, Armed Forces India.

[17]  M. Ghannoum,et al.  Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. , 2003, Infectious disease clinics of North America.

[18]  M. Ghannoum,et al.  Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.

[19]  V. Bindu,et al.  Clinico-mycological study of dermatophytosis in Calicut. , 2002, Indian journal of dermatology, venereology and leprology.

[20]  A. Gupta.  Butenafine: an update of its use in superficial mycoses. , 2002, Skin therapy letter.

[21]  S. Friedlander,et al.  Tinea capitis update: a continuing conflict with an old adversary , 2001, Current opinion in pediatrics.

[22]  A. LaMarca,et al.  Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. , 2001, Cutis (New York, N.Y.).

[23]  B. Elewski,et al.  The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. , 2001, Cutis.

[24]  R. Negroni,et al.  Mycoses associated with AIDS in the Third World. , 2000, Medical mycology.

[25]  S. Rand.  Overview: The treatment of dermatophytosis. , 2000, Journal of the American Academy of Dermatology.

[26]  R. Baird,et al.  Application of PCR to the identification of dermatophyte fungi. , 2000, Journal of medical microbiology.

[27]  N. Patwardhan,et al.  Dermatomycosis in and around Aurangabad. , 1999, Indian journal of pathology & microbiology.

[28]  L. Wiseman,et al.  Terbinafine. An update of its use in superficial mycoses. , 1999, Drugs.

[29]  A. Hasegawa,et al.  Phylogenetic Classification and Species Identification of Dermatophyte Strains Based on DNA Sequences of Nuclear Ribosomal Internal Transcribed Spacer 1 Regions , 1999, Journal of Clinical Microbiology.

[30]  R. Baird,et al.  Dermatophyte infections in Melbourne: trends from 1961/64 to 1995/96. , 1999, Pathology.

[31]  A. Mukhopadhyay,et al.  Itraconazole versus griseofulvine in the treatment of tinea corporis and tinea cruris. , 1995, Indian journal of dermatology, venereology and leprology.

[32]  M. Taha,et al.  One‐week therapy with oral terbinafine in cases of tinea cruris/corporis , 1994, The British journal of dermatology.

[33]  A. Finlay.  Global overview of Lamisil® , 1994, The British journal of dermatology.

[34]  V. Voravutinon.  Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. , 1993, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[35]  W. de Souza,et al.  Interaction of Trypanosoma cruzi with cells with altered glycosylation patterns. , 1993, Biochemical and biophysical research communications.

[36]  N. Ryder,et al.  Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.

[37]  S. López Gómez,et al.  A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris , 1990, Clinical and experimental dermatology.

[38]  G. Cole,et al.  A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. , 1989, Archives of dermatology.